In all patients (n = 98), ABBV-011 elicited a confirmed objective response rate (ORR) of 19% (95% CI, 12%-29%), with a clinical benefit rate (CBR) of 69% (95% CI, 59%-78%). Thirty-seven percent (95% CI, 27%-47%) of patients experienced a CBR that lasted for lon...
In this trial, patients who received ABBV-011 monotherapy had a confirmed overall response rate of 25%, including 10 partial responses, and the median duration of response was 4.2 months (95% CI, 2.6-6.7). Additionally, the clinical benefit rate was 65%, and the rate of clinica...